You are here

  • Home
  • Archive
  • Volume 11, Issue 12
  • Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

https://doi.org/10.1136/jitc-2023-007398corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meetze K, Mehta NK, Li B, et al. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression. J Immunother Cancer 2023;11:e007398. doi: 10.1136/jitc-2023-007398

    In this article, the authorship has been updated to include Hannah M Findlay, Timothy B London and Agapitos Patakas.